Overexpression of Indoleamine 2,3-Dioxygenase 1 Promotes Epithelial-Mesenchymal Transition by Activation of the IL-6/STAT3/PD-L1 Pathway in Bladder Cancer

A research team from Shanghai Tenth People’s Hospital, Tongji University, published a novel study about the role of Indoleamine 2,3-dioxygenase 1 (IDO1) in human bladder cancer.

This team used immunohistochemistry, Western blot, and quantitative reverse transcription-polymerase chain reaction experiments to compare the expression of protein and mRNA levels of IDO1 in bladder cancer tissues and cell lines to the noncancerous counterparts. The results show that IDO1 was overexpressed in bladder cancer tissues and cell lines. The expression of IDO1 was significantly correlated with tumor size, T stage, and N stage but not with other clinicopathological features, including age, gender, smoking history, etc. The result also indicates that knockdown of IDO1 inhibited EMT through the IL-6/STAT3/PD-L1 signaling pathway.

This study suggests the potential of inhibitors of IDO1 as a new therapy for human bladder cancer in the future.

Anogen’s human IL-6 ELISA kit was used in this article to measure the concentration of IL-6 in cell supernatant. There are a number of publications (that) studied the role of IL-6/STAT3/PD-L1 pathway in the development and progression of human cancers. Anogen is willing to support researches in IL-6/STAT3/PD-L1 pathway by providing high-quality IL-6 and PD-L1 ELISA Kits as well as antibodies.

For more information, please visit Anogen website: https://www.anogen.ca

Reference:

Wentao Zhang, Junfeng Zhang, Ziwei Zhang, Yadong Guo, Yuan Wu, Ruiliang Wang, Longsheng Wang, Shiyu Mao, Xudong Yao,

Overexpression of Indoleamine 2,3-Dioxygenase 1 Promotes Epithelial-Mesenchymal Transition by Activation of the IL-6/STAT3/PD-L1 Pathway in Bladder Cancer, Translational Oncology, Volume 12, Issue 3, 2019, Pages 485-492, ISSN 1936-5233, https://doi.org/10.1016/j.tranon.2018.11.012.